Sign In
Buy SVRA
$5.25
+0 (+0%)
At Close: Jun 03, 2026
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:32am, Friday, 27'th Mar 2026
Savara Inc. (NASDAQ: SVRA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports.
VR Adviser Adds Over 1 Million Savara Shares
10:39am, Sunday, 15'th Mar 2026
VR Adviser Bought 1,059,332 shares of Savara. Post-trade, VR Adviser held 13,740,375 shares valued at $82.9 million Savara represents 4.1% of the fund's AUM.
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
08:05am, Friday, 13'th Mar 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth qu
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received t
Savara Announces Participation in 2026 Citizens Life Sciences Conference
04:05pm, Wednesday, 04'th Mar 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the ma
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears
04:31am, Tuesday, 03'rd Mar 2026
Savara (NASDAQ: SVRA) executives highlighted recent regulatory and commercial milestones for its lead program, molgramostim inhalation solution (Molbreevi), during a discussion at Oppenheimer's 36th A
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the B
Savara Announces New Employment Inducement Grant
04:05pm, Friday, 13'th Feb 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new em
Savara Announces Participation in Upcoming Investor Healthcare Conferences
04:05pm, Wednesday, 04'th Feb 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its ma
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan an
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
Savara Announces New Employment Inducement Grant
04:05pm, Friday, 16'th Jan 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new
Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:16am, Thursday, 15'th Jan 2026
Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
04:05pm, Thursday, 08'th Jan 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the
